{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:20Z","timestamp":1791612440315,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: The popularity of GLP-1 receptor agonists (GLP-1 RAs) for weight loss has increased significantly in recent years, raising concerns about self-medication with these medications. Objective: To assess the proportion and identify factors associated with GLP-1 RA use without medical prescription among GLP-1 RA users in Brazil. Methods: This cross-sectional study was conducted through a self-administered online questionnaire including adults aged 18 years or older residing in Brazil who reported current or past use of GLP-1 RAs for weight loss. We reported the proportion of self-medication and explored associated factors using Poisson regression with robust variance, adjusting for potential confounders. Results: A total of 860 participants were included (mean age: 39.46\u2009\u00b1\u200910.61 years; 82.0% female; 47.1% with obesity). The proportion of self-medication with GLP-1 RA was 23.8% (95% CI: 21.1\u201326.8%). Predictors of self-medication included not having obesity (PR\u2009=\u20091.45; 95% CI: 1.13\u20131.89), not attending physical training centers (PR\u2009=\u20091.55; 95% CI: 1.23\u20131.96), and working in healthcare-related professions (PR\u2009=\u20091.45; 95% CI: 1.14\u20131.84). Conversely, being married (PR\u2009=\u20090.73; 95% CI: 0.57\u20130.94), having diabetes (PR\u2009=\u20090.35; 95% CI: 0.18\u20130.70), or having eating disorders (PR\u2009=\u20090.72; 95% CI, 0.34\u20130.97) were associated with lower self-medication rates. Conclusion: Almost one in four users reported using GLP-1 RAs without medical prescription. This practice was more frequent among individuals without obesity, those not attending physical training centers, and healthcare professionals.<\/jats:p>","DOI":"10.1038\/s41366-026-02186-0","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:44:23Z","timestamp":1787179463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Self-medication with GLP-1 receptor agonists among Brazilian Adults: findings from a web-based survey"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1693-3206","authenticated-orcid":false,"given":"Ta\u00edse Rosa","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3934-6848","authenticated-orcid":false,"given":"Lucas S.","family":"Matzenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Gomes Boabaid de","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza Machado","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Kude","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Gabriela Rodrigues","family":"Haussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-7633","authenticated-orcid":false,"given":"Jacqueline","family":"Rizzolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Heiden","family":"Telo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2186_CR1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1001\/jamainternmed.2023.8526","volume":"184","author":"SZ Yanovski","year":"2024","unstructured":"Yanovski SZ, Yanovski JA. Approach to obesity treatment in primary care: a review. JAMA Intern Med. 2024;184:818\u201329.","journal-title":"JAMA Intern Med"},{"key":"2186_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"2186_CR3","first-page":"331","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:331\u201344.","journal-title":"N Engl J Med"},{"key":"2186_CR4","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M, et al. Obesity management in adults: a review. JAMA. 2023;330:2000\u201315.","journal-title":"JAMA"},{"key":"2186_CR5","doi-asserted-by":"crossref","unstructured":"Chiappini S, Vickers-Smith R, Harris D, Papanti GD, Corkery JM, Guirguis A, et al. Is there a risk for semaglutide misuse? Focus on the FDA adverse events reporting system (FAERS) pharmacovigilance dataset. Pharmaceuticals. 2023;16:994.","DOI":"10.3390\/ph16070994"},{"key":"2186_CR6","doi-asserted-by":"publisher","first-page":"1124.","DOI":"10.3390\/biomedicines12051124","volume":"12","author":"A Butuca","year":"2024","unstructured":"Butuca A, Dobrea CM, Arseniu AM, Frum A, Chis AA, Rus LL, et al. An assessment of semaglutide safety based on real-world data: from popularity to spontaneous reporting in EudraVigilance database. Biomedicines. 2024;12:1124.","journal-title":"Biomedicines"},{"key":"2186_CR7","doi-asserted-by":"publisher","first-page":"e26121243905.","DOI":"10.33448\/rsd-v12i12.43905","volume":"12","author":"SP Pires","year":"2023","unstructured":"Pires SP, Leal BA, Souza IP, Rangel KCF, Santos Filho LE. Use of semaglutide for aesthetic and weight loss purposes by non-diabetic individuals. Res Soc Dev. 2023;12:e26121243905.","journal-title":"Res Soc Dev"},{"key":"2186_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","volume":"44","author":"AI Guerdjikova","year":"2024","unstructured":"Guerdjikova AI, Ward A, Ontiveros M, McElroy SL. Semaglutide misuse in atypical anorexia nervosa: a case report. J Clin Psychopharmacol. 2024;44:179\u201380.","journal-title":"J Clin Psychopharmacol"},{"key":"2186_CR9","first-page":"301","volume":"29","author":"L Orsolini","year":"2014","unstructured":"Orsolini L, Francesconi G, Papanti D, Giorgetti A, Schifano F. Profiling online recreational\/prescription drugs\u2019 customers and overview of drug vending virtual marketplaces. Hum Psychopharmacol. 2014;29:301\u201310.","journal-title":"Hum Psychopharmacol"},{"key":"2186_CR10","unstructured":"US Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain [Internet]. 2025 [cited 2025 Apr 26]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain."},{"key":"2186_CR11","unstructured":"US Food and Drug Administration. FDA\u2019s concerns with unapproved GLP-1 drugs used for weight loss [Internet]. 2025 [cited 2025 Apr 27]. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss."},{"key":"2186_CR12","doi-asserted-by":"publisher","unstructured":"BMJ. GLP-1 receptor agonists: safety concerns [Internet]. 2024 Feb 24 [cited 2025 Apr 27];388:r390. Available from: https:\/\/doi.org\/10.1135\/bmj.r390.","DOI":"10.1135\/bmj.r390"},{"key":"2186_CR13","doi-asserted-by":"crossref","unstructured":"Linhares IS, Cardoso OO, Andrade JX, Nascimento FFD, Rodrigues MTP, Mascarenhas MDM, et al. Prevalence and factors associated with body image dissatisfaction among school students: National School Health Survey, 2019. Epidemiol Serv Saude. 2024;33.","DOI":"10.1590\/s2237-96222024v33e20231441.en"},{"key":"2186_CR14","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Medicamentos agonistas GLP-1 s\u00f3 poder\u00e3o ser vendidos com reten\u00e7\u00e3o da receita [Internet]. 2025 [cited 2025 May 1]. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2024\/canetas-emagrecedoras-so-poderao-ser-vendidas-com-retencao-de-receita."},{"key":"2186_CR15","unstructured":"G1. Semaglutida para tratar obesidade \u00e9 cada vez mais usada para fins est\u00e9ticos; conhe\u00e7a os riscos da automedica\u00e7\u00e3o [Internet]. 2025 [cited 2025 Apr 26]. Available from: https:\/\/g1.globo.com\/fantastico\/noticia\/2023\/2\/4\/medicamento-semaglutida-para-tratar-obesidade-e-cada-vez-mais-usado-para-fins-esteticos-conheca-os-riscos-da-automedicacao.ghtml."},{"key":"2186_CR16","doi-asserted-by":"publisher","first-page":"1176730","DOI":"10.3389\/fpubh.2023.1176730","volume":"11","author":"CT Nguyen","year":"2023","unstructured":"Nguyen CT, Nguyen HT, Boyer L, Auquier P, Fond G, Do KN, et al. Prevalence and impacts of self-medication in a disadvantaged setting: the importance of multidimensional health interventions. Front Public Health. 2023;11:1176730","journal-title":"Front Public Health"},{"key":"2186_CR17","unstructured":"Dean AG, Sullivan KM, Soe MM. OpenEpi: open source epidemiologic statistics for public health [Internet]. Available from: www.OpenEpi.com."},{"key":"2186_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The STROBE statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"2186_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11695-020-04987-2","volume":"31","author":"A Elangovan","year":"2021","unstructured":"Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity: trends using a population-level national database. Obes Surg. 2021;31:1101\u20139.","journal-title":"Obes Surg"},{"key":"2186_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/oby.21533","volume":"21","author":"CE Thomas","year":"2016","unstructured":"Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of weight loss medications: a comparison of prescribing patterns of anti-obesity pharmacotherapies and SGLT2 inhibitors. Obesity. 2016;21:1955\u201361.","journal-title":"Obesity"},{"key":"2186_CR21","doi-asserted-by":"publisher","first-page":"e2428280.","DOI":"10.1001\/jamanetworkopen.2024.28280","volume":"8","author":"AR Ashraf","year":"2024","unstructured":"Ashraf AR, Mackey TK, Schmidt J, Kulcs\u00e1r G, Vida RG, Li J, et al. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open. 2024;8:e2428280.","journal-title":"JAMA Netw Open"},{"key":"2186_CR22","doi-asserted-by":"publisher","first-page":"e245015.","DOI":"10.1001\/jamahealthforum.2024.5015","volume":"7","author":"TJ Mattingly","year":"2025","unstructured":"Mattingly TJ, Conti RM. Marketing and safety concerns for compounded GLP-1 receptor agonists. JAMA Health Forum. 2025;7:e245015.","journal-title":"JAMA Health Forum"},{"key":"2186_CR23","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). G\u00eanero [Internet]. Rio de 401Janeiro:IBGE;[citado2026Jun7].Dispon\u00edvelem: 402 https:\/\/www.ibge.gov.br\/estatisticas\/multidominio\/genero.html."}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02186-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:44:25Z","timestamp":1787179465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02186-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":23,"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02186-0","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}